NRX-0305 / Nurix Therap - LARVOL DELTA

NRX-0305 is an orally bioavailable, pan-mutant BRAF degrader that exhibits single-agent and combination efficacy with MEKi or anti-EGFR across Class 1/2/3 BRAF-mutant cancers (AACR 2026) - "In vivo, daily oral administration of NRX-0305 induced robust, dose-dependent BRAF degradation and pathway inhibition, producing marked single-agent efficacy in multiple Class 1/2/3 cell lines-derived xenograft and patient-derived xenograft models. Furthermore, combination studies of NRX-0305 with MEK inhibitor or anti-EGFR demonstrated enhanced antitumor activity, supporting its potential use in clinically relevant combination regimens.Collectively, these studies demonstrate NRX-0305 is a potent, mutant-selective BRAF degrader that can overcome the limitations of approved BRAF inhibitors, offering broad therapeutic potential both as a single agent and in combination with MEKi or anti-EGFR antibodies across Class 1/2/3 BRAF-mutant cancers."

Clinical • Colorectal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF

NRX-0305, an orally bioavailable, CNS penetrant pan-mutant BRAF degrader demonstrates robust efficacy in intracranial models of melanoma brain metastasis and primary glioma (AACR 2026) - "Daily oral administration of NRX-0305 demonstrated potent single-agent efficacy in multiple intracranial models of BRAF-mutant melanoma and glioma. In a BRAF inhibitor-resistant melanoma brain metastasis PDX model, NRX-0305 achieved dose-dependent efficacy and significantly improved survival relative to vehicle and dabrafenib treatment, demonstrating superiority to clinically approved BRAF inhibitors.These findings establish pan-mutant BRAF degradation as a promising therapeutic strategy for BRAF-mutant CNS malignancies and highlight NRX-0305's potential to overcome the limited CNS activity and treatment-emergent resistance associated with BRAF targeted therapies."

Clinical • Brain Cancer • Cutaneous Melanoma • Glioma • Melanoma • Oncology • Solid Tumor • BRAF

NRX-0305: a pan-mutant BRAF degrader with broad preclinical efficacy, brain penetrance, and synergistic potential with MEKi across class 1/2/3 BRAF-mutant cancers (AACR 2025) - "Furthermore, NRX-0305 in combination with MEK inhibition achieves complete tumor regression in a Class 3 bladder cancer PDX model, demonstrating its synergistic potential. These findings establish mutant-specific BRAF degradation as a promising therapeutic strategy, displaying activity across a broad range of mutations and addressing the limitations of BRAFi in Class 1/2/3 BRAF-mutant cancers."

Preclinical • Bladder Cancer • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets (GlobeNewswire) - "In a second poster titled: NRX-0305: a pan-mutant BRAF degrader with broad preclinical efficacy, brain penetrance, and synergistic potential with MEKi across class 1/2/3 BRAF-mutant cancers, preclinical data were presented from Nurix’s differentiated BRAF degrader, NRX-0305, which degrades all three classes of mutant oncogenic BRAF proteins while sparing wildtype BRAF in healthy cells....In disease models, data demonstrated broad anti-tumor efficacy of NRX-0305 across all three BRAF mutation classes and in tumors that are resistant to existing therapies. Specifically, NX-0305 demonstrated superior anti-tumor efficacy in a xenograft (PDX) model derived from a patient with a class 1 BRAF mutation whose tumor was resistant to both pembrolizumab + BRAFi compared to a competitor BRAF degrader CFT1946."

Preclinical • Solid Tumor

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting (GlobeNewswire) - "Nurix Therapeutics...announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentations and two poster presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting..."

Preclinical • Oncology

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit (GlobeNewswire) - "Nurix Therapeutics...announced that members of the Nurix team will make oral presentations on Nurix programs and participate in several industry panel discussions at the 7th Annual TPD & Induced Proximity Summit, being held October 28–31, 2024, in Boston, MA....'We are excited to share preclinical data from our previously undisclosed pan-mutant B-Raf selective degrader with CNS exposure along with a review of clinical data from our NX-5948 selective BTK degrader with updated case reports'."

Clinical data • Preclinical • Oncology • Solid Tumor